Protalix BioTherapeutics (NYSE:PLX – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a note issued to investors on Thursday. Separately, HC Wainwright ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback